ArticleJournal of nanobiotechnology2026
Injectable ROS-scavenging and NIR-responsive nanocomposite hydrogel for staphylococcus aureus-infected diabetic wound healing.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Chronic diabetic wounds are often complicated by persistent infections and oxidative stress, which impede effective healing. In this study, we developed an injectable, dual-responsive nanocomposite hydrogel designed to simultaneously scavenge reactive oxygen species (ROS) and deliver photothermal and photodynamic therapy for wound treatment. The hydrogel was synthesized via dynamic boronate-ester crosslinking of poly(vinyl alcohol) (PVA) with a bis-boronic acid linker (TSPBA), enabling efficient ROS quenching. Incorporation of palygorskite/molybdenum disulfide (PGS/MoS₂) nanocomposites imparted photothermal and photodynamic properties, activated by NIR light. In vitro tests demonstrated that the PVA-TSPBA@PGS/MoS₂ hydrogel effectively scavenged ROS, induced mild hyperthermia (~ 48 °C) under NIR, and exhibited significant antibacterial activity against Staphylococcus aureus. In vivo, the hydrogel accelerated wound closure in a diabetic mouse model, with a 46.7% residual area at day 7, compared to higher residual areas in control groups (66.5-92.4%). By day 14, nearly complete wound healing was achieved, accompanied by reduced bacterial load and inflammatory markers, as well as enhanced re-epithelialization, angiogenesis, and collagen remodeling. These findings suggest that this multifunctional hydrogel represents a promising strategy for the treatment of infected diabetic wounds, offering a controlled, localized approach to wound healing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.